Teleflex reports Q1 adjusted EPS $1.39, consensus $1.22

Reports Q1 revenue $548.3M, consensus $537.59M. “Our Q1 performance reflects disciplined execution and meaningful progress against our transformation plan,” said CEO Stuart Randle. “We delivered a strong start to the year, with 5.1% pro forma adjusted constant currency revenue growth year-over-year, and we continue to expect our two strategic divestitures to close in the second half of 2026. We remain committed to using the majority of the net proceeds from the sales transactions to return capital to shareholders through our $1B share repurchase authorization, while also reducing debt by $800M to enhance financial flexibility and support future growth. These actions are advancing our strategy to optimize our portfolio, strengthen Teleflex’s (TFX) position as a focused medical technologies leader and drive long-term value creation”.